FDA DEVICE FACTS
ProstatID
Scanmed, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
INDICATIONS FOR USE: ProstatID™ is a radiological computer assisted detection (CADe) and diagnostic (CADx) software device for use in a healthcare facility or hospital to assist trained radiologists in the detection, assessment and characterization of prostate abnormalities, including cancer lesions using MR image data with the following indications for use. ProstatID analyzes T2W, DWI and ADC MRI data. ProstatID does not include DCE images in its analysis. ProstatID software is intended for use as a concurrent reading aid for physicians interpreting prostate MRI exams of patients presented for high-risk screening or diagnostic imaging, from compatible MRI systems, to identify regions suspicious for prostate cancer and assess their likelihood of malignancy. Outputs of the device include the volume of the prostate and locations, as well as the extent of suspect lesions, with index scores indicating the likelihood that cancer is present, as well as an exam score by way of PI-RADS interpretation suggestion. "Extent of suspect lesions" refers to both the assessment of the boundary of a particular abnormality, as well as identification of multiple abnormalities. In cases where multiple abnormalities are present, ProstatID can be used to assess each abnormality independently. Outputs of this device should be interpreted with all available MR data consistent with ACR clinical recommendations (e.g., dynamic contrast enhanced images if available) in context of PI-RADS v2, and in conjunction with bi-parametric MRI acquired with either surface or endorectal MRI accessory coils from compatible MRI systems. Analysis by ProstatID is not intended as a replacement for interpreting prostate abnormalities using MR image data consistent with clinical recommendations (including DCE); nor should patient management decisions be made solely on the basis of ProstatID. INTENDED USER POPULATION Intended users of ProstatID are physicians qualified to read and interpret prostate MRI exams consistent with ACR recommendations in the context of PI-RADS v2. INTENDED PATIENT POPULATION The device is intended to be used in the population of biological adult males with a prostate gland undergoing screening or clinical MRI exams. This includes biological males with clinical indicators suggestive of possible prostate cancer or with family history of prostate cancer.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。